Ng SY, Lee AYW. Traumatic mind accidents: pathophysiology and potential therapeutic targets. Entrance Cell Neurosci. 2019;13:528.
Werner C, Engelhard Ok. Pathophysiology of traumatic mind harm. Br J Anaesth. 2007;99:4–9.
Khellaf A, Khan DZ, Helmy A. Current advances in traumatic mind harm. J Neurol. 2019;266:2878–89.
Cai L, Gong Q, Qi L, Xu T, Suo Q, Li X, Wang W, Jing Y, Yang D, Xu Z, et al. ACT001 attenuates microglia-mediated neuroinflammation after traumatic mind harm through inhibiting AKT/NFκB/NLRP3 pathway. Cell Commun Sign. 2022;20:56.
Abdul-Muneer P, Chandra N, Haorah J. Interactions of oxidative stress and neurovascular irritation within the pathogenesis of traumatic mind harm. Mol Neurobiol. 2015;51:966–79.
Readnower RD, Chavko M, Adeeb S, Conroy MD, Pauly JR, McCarron RM, et al. Improve in blood–mind barrier permeability, oxidative stress, and activated microglia in a rat mannequin of blast-induced traumatic mind harm. J Neurosci Res. 2010;88:3530–9.
Blennow Ok, Brody DL, Kochanek PM, Levin H, McKee A, Ribbers GM, et al. Traumatic mind accidents. Nat Rev Dis Primers. 2016;2:1–19.
Maas AI, Menon DK, Manley GT, Abrams M, Åkerlund C, Andelic N, et al. Traumatic mind harm: progress and challenges in prevention, medical care, and analysis. Lancet Neurol. 2022;21:1004–60.
Ballabh P, Braun A, Nedergaard M. The blood–mind barrier: an summary: construction, regulation, and medical implications. Neurobiol Dis. 2004;16:1–13.
Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–mind barrier: construction, regulation and drug supply. Sign Transduct Goal Ther. 2023;8:217.
Ma X, Zhao Y, Liang X-J. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011;44:1114–22.
Kim Y, Kim J, An JM, Park C-Ok, Kim D. All-nontoxic fluorescent probe for biothiols and its medical functions for real-time glioblastoma visualization. ACS Sens. 2023;8:1723–32.
Kim J, Um H, Kim NH, Kim D. Potential Alzheimer’s illness therapeutic nano-platform: discovery of amyloid-beta plaque disaggregating agent and brain-targeted supply system utilizing porous silicon nanoparticles. Bioact Mater. 2023;24:497–506.
Kang RH, Jang J-E, Huh E, Kang SJ, Ahn D-R, Kang JS, et al. A mind tumor-homing tetra-peptide delivers a nano-therapeutic for simpler remedy of a mouse mannequin of glioblastoma. Nanoscale Horiz. 2020;5:1213–25.
Brahmi M, Bakirhan NK. Improvements in traumatic mind harm diagnostics: electrochemical impedance spectroscopy main the way in which. J Appl Electrochem. 2024;55:1–17.
Dhull A, Zhang Z, Sharma R, Dar AI, Rani A, Wei J, Gopalakrishnan S, Ghannam A, Hahn V, Pulukuri AJ, et al. Discovery of 2-deoxy glucose surfaced combined layer dendrimer: a wise neuron focused systemic drug supply system for mind illnesses. Theranostics. 2024;14:3221–45.
McHugh EA, Liopo AV, Mendoza Ok, Robertson CS, Wu G, Wang Z, Chen W, Beckham JL, Derry PJ, Kent TA, Tour JM. Oxidized activated charcoal nanozymes: synthesis, and optimization for in vitro and in vivo bioactivity for traumatic mind harm. Adv Mater. 2024;36:e2211239.
Robbins EM, Wong B, Pwint MY, Salavatian S, Mahajan A, Cui XT. Enhancing sensitivity and longevity of in vivo glutamate sensors with electrodeposited nanopt. ACS Appl Mater Interfaces. 2024;16:40570–80.
Rubby MF, Fonder C, Uchayash S, Liang X, Sakaguchi DS, Que L. Evaluation of the behaviors of an in vitro mind mannequin on-chip underneath shockwave impacts. ACS Appl Mater Interfaces. 2024;16:33246–58.
Kim Y, An JM, Kim J, Chowdhury T, Yu HJ, Kim Ok-M, Kang H, Park C-Ok, Joung JF, Park S. Pyridine-NBD: A homocysteine-selective fluorescent probe for glioblastoma (GBM) analysis primarily based on a blood check. Anal Chim Acta. 2022;1202:339678.
Singha S, Kim D, Rao AS, Wang T, Kim KH, Lee Ok-H, et al. Two-photon probes primarily based on arylsulfonyl azides: fluorescence detection and imaging of biothiols. Dyes Pigments. 2013;99:308–15.
Zuidema JM, Kumeria T, Kim D, Kang J, Wang J, Hollett G, Zhang X, Roberts DS, Chan N, Dowling C. Oriented nanofibrous polymer scaffolds containing protein-loaded porous silicon generated by spray nebulization. Adv Mater. 2018;30:1706785.
Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, Petroni G, Lujan S, Pridgeon J, Barber J. A trial of intracranial-pressure monitoring in traumatic mind harm. N Engl J Med. 2012;367:2471–81.
Guan B, Anderson DB, Chen L, Feng S, Zhou H. World, regional and nationwide burden of traumatic mind harm and spinal twine harm, 1990–2019: a scientific evaluation for the worldwide burden of illness research 2019. BMJ Open. 2023;13:e075049.
James SL, Theadom A, Ellenbogen RG, Bannick MS, Montjoy-Venning W, Lucchesi LR, et al. World, regional, and nationwide burden of traumatic mind harm and spinal twine harm, 1990–2016: a scientific evaluation for the worldwide burden of illness research 2016. Lancet Neurol. 2019;18:56–87.
Stein MB, Kessler RC, Heeringa SG, Jain S, Campbell-Sills L, Colpe LJ, et al. Potential longitudinal analysis of the impact of deployment-acquired traumatic mind harm on posttraumatic stress and associated issues: outcomes from the military research to evaluate danger and resilience in servicemembers (Military STARRS). Am J Psychiatry. 2015;172:1101–11.
Johnson BD. Sports activities-related subconcussive head trauma. Concussions Athletics: Mind Behav. 2021;249–69.
Bruns J Jr, Hauser WA. The epidemiology of traumatic mind harm: a evaluate. Epilepsia. 2003;44:2–10.
Fernandes FAO. Biomechanical evaluation of helmeted head impacts: novel supplies and geometries. Universidade de Aveiro (Portugal); 2019.
Johnson WD, Griswold DP. Traumatic mind harm: a worldwide problem. Lancet Neurol. 2017;16:949–50.
Roozenbeek B, Maas AI, Menon DK. Altering patterns within the epidemiology of traumatic mind harm. Nat Rev Neurol. 2013;9:231–6.
Harvey LA, Shut JC. Traumatic mind harm in older adults: traits, causes and penalties. Harm. 2012;43:1821–6.
Thompson HJ, McCormick WC, Kagan SH. Traumatic mind harm in older adults: epidemiology, outcomes, and future implications. J Am Geriatr Soc. 2006;54:1590–5.
Toth L, Czigler A, Horvath P, Kornyei B, Szarka N, Schwarcz A, Ungvari Z, Buki A, Toth P. Traumatic mind injury-induced cerebral microbleeds within the aged. Geroscience. 2021;43:125–36.
Reger MA, Brenner LA, du Pont A. Traumatic mind harm and veteran mortality after the conflict in Afghanistan. JAMA Netw Open. 2022;5:e2148158-2148158.
Stein DG, Geddes RI, Sribnick EA. Current developments in medical trials for the remedy of traumatic mind harm. Handb Clin Neurol. 2015;127:433–51.
DePalma RG, Hoffman SW. Fight blast associated traumatic mind harm (TBI): decade of recognition; promise of progress. Behav Mind Res. 2018;340:102–5.
Duckworth JL, Grimes J, Ling GS. Pathophysiology of battlefield related traumatic mind harm. Pathophysiology. 2013;20:23–30.
Marklund N. Blast-Induced Mind Harm. Administration of Extreme Traumatic Mind Harm: Proof, Tips, and Pitfalls 2020:109–113.
Aravind A, Ravula AR, Chandra N, Pfister BJ. Behavioral deficits in animal fashions of blast traumatic mind harm. Entrance Neurol. 2020;11:990.
Bugay V, Bozdemir E, Vigil FA, Chun SH, Holstein DM, Elliott WR, et al. A mouse mannequin of repetitive blast traumatic mind harm reveals post-trauma seizures and elevated neuronal excitability. J Neurotrauma. 2020;37:248–61.
Tomura S, Seno S, Kawauchi S, Miyazaki H, Sato S, Kobayashi Y, et al. A novel mouse mannequin of gentle traumatic mind harm utilizing laser-induced shock waves. Neurosci Lett. 2020;721:134827.
Kandell RM, Kudryashev JA, Kwon EJ. Concentrating on the extracellular matrix in traumatic mind harm will increase sign era from an activity-based nanosensor. ACS Nano. 2021;15:20504–16.
Kandell RM, Wu JR, Kwon EJ. Reprogramming clots for in vivo chemical concentrating on in traumatic mind harm. Adv Mater. 2024;2301738.
Nikolian VC, Dekker SE, Bambakidis T, Higgins GA, Dennahy IS, Georgoff PE, et al. Enchancment of blood-brain barrier integrity in traumatic mind harm and hemorrhagic shock following remedy with valproic acid and recent frozen plasma. Crit Care Med. 2018;46:e59-66.
Salehi A, Zhang JH, Obenaus A. Response of the cerebral vasculature following traumatic mind harm. J Cereb Blood Move Metab. 2017;37:2320–39.
Winkler EA, Minter D, Yue JK, Manley GT. Cerebral edema in traumatic mind harm: pathophysiology and potential therapeutic targets. Neurosurg Clin N Am. 2016;27:473–88.
Maas AI, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic mind harm: built-in approaches to enhance prevention, medical care, and analysis. Lancet Neurol. 2017;16:987–1048.
Meyfroidt G, Bouzat P, Casaer MP, Chesnut R, Hamada SR, Helbok R, Hutchinson P, Maas AI, Manley G, Menon DK. Administration of average to extreme traumatic mind harm: an replace for the intensivist. Intensive Care Med. 2022;48:649–66.
van Erp IA, Michailidou I, van Essen TA, van der Jagt M, Moojen W, Peul WC, Baas F, Fluiter Ok. Tackling neuroinflammation after traumatic mind harm: complement Inhibition as a remedy for secondary harm. Neurotherapeutics. 2023;20:284–303.
Zhang X, Huang X, Cling D, Jin J, Li S, Zhu Y, et al. Concentrating on pyroptosis with nanoparticles to alleviate neuroinflammatory for stopping secondary injury following traumatic mind harm. Sci Adv. 2024;10:eadj4260.
Bharadwaj VN, Nguyen DT, Kodibagkar VD, Stabenfeldt SE. Nanoparticle-based therapeutics for mind harm. Adv Healthc Mater. 2018;7:1700668.
Mohammed FS, Omay SB, Sheth KN, Zhou J. Nanoparticle-based drug supply for the remedy of traumatic mind harm. Skilled Opin Drug Deliv. 2023;20:55–73.
Silva GA. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol. 2005;63:301–6.
Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A scientific evaluate of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015;5(6):506–19.
Saatman KE, Creed J, Raghupathi R. Calpain as a therapeutic goal in traumatic mind harm. Neurotherapeutics. 2010;7:31–42.
Cagmat EB, Guingab-Cagmat JD, Vakulenko AV, Hayes RL, Anagli J. Potential use of calpain inhibitors as mind harm remedy. 2015.
Kudryashev JA, Waggoner LE, Leng HT, Mininni NH, Kwon EJ. An activity-based nanosensor for traumatic mind harm. ACS Sens. 2020;5:686–92.
Baudry M, Luo YL, Bi X. Calpain-2 inhibitors as remedy for traumatic mind harm. Neurotherapeutics. 2023;20:1592–602.
Schoch KM, Von Reyn CR, Bian J, Telling GC, Meaney DF, Saatman KE. Mind injury-induced proteolysis is lowered in a novel calpastatin‐overexpressing transgenic mouse. J Neurochem. 2013;125:909–20.
Bains M, Cebak JE, Gilmer LK, Barnes CC, Thompson SN, Geddes JW, et al. Pharmacological evaluation of the cortical neuronal cytoskeletal protecting efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic mind harm mannequin. J Neurochem. 2013;125:125–32.
Andriessen TM, Jacobs B, Vos PE. Medical traits and pathophysiological mechanisms of focal and diffuse traumatic mind harm. J Cell Mol Med. 2010;14:2381–92.
Czogalla A, Sikorski A. Spectrin and calpain: a ‘goal’and a ‘sniper’within the pathology of neuronal cells. Cell Mol Life Sci. 2005;62:1913–24.
Gan ZS, Stein SC, Swanson R, Guan S, Garcia L, Mehta D, Smith DH. Blood biomarkers for traumatic mind harm: a quantitative evaluation of diagnostic and prognostic accuracy. Entrance Neurol. 2019;10:446.
Hamakubo T, Kannagi R, Murachi T, Matus A. Distribution of calpains I and II in rat mind. J Neurosci. 1986;6:3103–11.
Siman R, Giovannone N, Hanten G, Wilde EA, McCauley SR, Hunter JV, Li X, Levin HS, Smith DH. Proof that the blood biomarker SNTF predicts mind imaging adjustments and protracted cognitive dysfunction in gentle TBI sufferers. Entrance Neurol. 2013;4:190.
Wang KK, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall JA, et al. An replace on diagnostic and prognostic biomarkers for traumatic mind harm. Skilled Rev Mol Diagn. 2018;18:165–80.
Yan X-X, Jeromin A. Spectrin breakdown merchandise (SBDPs) as potential biomarkers for neurodegenerative illnesses. Curr Transl Geriatr Exp Gerontol Rep. 2012;1:85–93.
Madias MI, Stessman LN, Warlof SJ, Kudryashev JA, Kwon EJ. Spatial measurement and inhibition of calpain exercise in traumatic mind harm with an activity-based nanotheranostic platform. ACS Nano. 2024;18:25565–76.
Han Z, Han Y, Huang X, Ma H, Zhang X, Tune J, Dong J, Li S, Yu R, Liu H. A novel focused nanoparticle for traumatic mind harm remedy: mixed impact of ROS depletion and calcium overload Inhibition. Adv Healthc Mater. 2022;11:2102256.
Shohami E, Kohen R. The position of reactive oxygen species within the pathogenesis of traumatic mind harm. Oxidative Stress Free Radical Injury Neurol 2011; 99–118.
Kowaltowski AJ, Vercesi AE. Mitochondrial injury induced by situations of oxidative stress. Free Radic Biol Med. 1999;26:463–71.
Lewén A, Matz P, Chan PH. Free radical pathways in CNS harm. J Neurotrauma. 2000;17:871–90.
Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U. Mitochondrial membrane fluidity and oxidative injury to mitochondrial DNA in aged and AD human mind. Mol Chem Neuropathol. 1997;31:53–64.
Pandya JD, Musyaju S, Modi HR, Cao Y, Flerlage WJ, Huynh L, Kociuba B, Visavadiya NP, Kobeissy F, Wang Ok. Complete analysis of mitochondrial redox profile, calcium dynamics, membrane integrity and apoptosis markers in a preclinical mannequin of extreme penetrating traumatic mind harm. Free Radic Biol Med. 2023;198:44–58.
Yang Y, Li Z, Fan X, Jiang C, Wang J, Rastegar-Kashkooli Y, Wang TJ, Wang J, Wang M, Cheng N, et al. Nanozymes: potential therapies for reactive oxygen species overproduction and irritation in ischemic stroke and traumatic mind harm. ACS Nano. 2024;18:16450–67. https://doi.org/10.1021/acsnano.4c03425
Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood–mind barrier breakdown as a therapeutic goal in traumatic mind harm. Nat Rev Neurol. 2010;6:393–403.
Bharadwaj VN, Lifshitz J, Adelson PD, Kodibagkar VD, Stabenfeldt SE. Temporal evaluation of nanoparticle accumulation after experimental mind harm: impact of particle measurement. Sci Rep. 2016;6:29988.
Boyd BJ, Galle A, Daglas M, Rosenfeld JV, Medcalf R. Traumatic mind harm opens blood–mind barrier to stealth liposomes through an enhanced permeability and retention (EPR)-like impact. J Drug Goal. 2015;23:847–53.
Waggoner LE, Kang J, Zuidema JM, Vijayakumar S, Hurtado AA, Sailor MJ, et al. Porous silicon nanoparticles focused to the extracellular matrix for therapeutic protein supply in traumatic mind harm. Bioconjug Chem. 2022;33:1685–97.
Waggoner LE, Madias MI, Hurtado AA, Kwon EJ. Pharmacokinetic evaluation of peptide-modified nanoparticles with engineered physicochemical properties in a mouse mannequin of traumatic mind harm. AAPS J. 2021;23:100.
Yoo D, Magsam AW, Kelly AM, Stayton PS, Kievit FM, Convertine AJ. Core-cross-linked nanoparticles cut back neuroinflammation and enhance final result in a mouse mannequin of traumatic mind harm. ACS Nano. 2017;11:8600–11.
Cernak I, Savic J, Ignjatovic D, Jevtic M. Blast harm from explosive munitions. J Trauma Acute Care Surg. 1999;47:96–103.
Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A managed cortical affect mannequin of traumatic mind harm within the rat. J Neurosci Strategies. 1991;39:253–62.
Duhaime A-C. Giant animal fashions of traumatic harm to the immature mind. Dev Neurosci. 2006;28:380–7.
Duhaime A-C, Margulies SS, Durham SR, O’Rourke MM, Golden JA, Marwaha S, et al. Maturation-dependent response of the piglet mind to scaled cortical affect. J Neurosurg. 2000;93:455–62.
Dutchke J, Anderson R, Sandoz B, Finnie J, Manavis J, Nishimoto T, Morris T, Wells A, Turner R, Vink R. A biomechanical mannequin of traumatic contusional harm produced by managed cerebrocortical indentation in sheep. In IRCOBI Convention Proceedings. 2016: 354–368.
King C, Robinson T, Dixon CE, Rao GR, Larnard D, Nemoto CEM. Mind temperature profiles throughout epidural cooling with the chillerpad in a monkey mannequin of traumatic mind harm. J Neurotrauma. 2010;27:1895–903.
Leung LY, Larimore Z, Holmes L, Cartagena C, Mountney A, Deng-Bryant Y, Schmid Ok, Shear D, Tortella F. The WRAIR projectile concussive affect mannequin of gentle traumatic mind harm: re-design, testing and preclinical validation. Ann Biomed Eng. 2014;42:1618–30.
Lighthall JW. Managed cortical affect: a brand new experimental mind harm mannequin. J Neurotrauma. 1988;5:1–15.
Namjoshi DR, Cheng WH, McInnes KA, Martens KM, Carr M, Wilkinson A, et al. Merging pathology with biomechanics utilizing CHIMERA (Closed-Head affect mannequin of engineered rotational Acceleration): a novel, surgery-free mannequin of traumatic mind harm. Mol Neurodegener. 2014;9:1–18.
Romine J, Gao X, Chen J. Managed cortical affect mannequin for traumatic mind harm. J Visualized Experiments: JoVE 2014;51781.
Williams AJ, Hartings JA, Lu X-CM, Rolli ML, Dave JR, Tortella FC. Characterization of a brand new rat mannequin of penetrating ballistic mind harm. J Neurotrauma. 2005;22:313–31.
Laurer HL, Lenzlinger PM, McIntosh TK. Fashions of traumatic mind harm. Eur J Trauma. 2000;26:95–110.
Lisi I, Moro F, Mazzone E, Marklund N, Pischiutta F, Kobeissy F, Mao X, Corrigan F, Helmy A, Nasrallah F. Exploiting blood-based biomarkers to align preclinical fashions with human traumatic mind harm. Mind. 2025;148:1062–80.
Petersen A, Soderstrom M, Saha B, Sharma P. Animal fashions of traumatic mind harm: a evaluate of pathophysiology to biomarkers and coverings. Exp Mind Res. 2021;239:2939–50.
Adelson PD, Ragheb J, Muizelaar JP, Kanev P, Brockmeyer D, Beers SR, Brown SD, Cassidy LD, Chang Y, Levin H. Part II medical trial of average hypothermia after extreme traumatic mind harm in youngsters. Neurosurgery. 2005;56:740–54.
Adelson PD, Wisniewski SR, Beca J, Brown SD, Bell M, Muizelaar JP, et al. Comparability of hypothermia and normothermia after extreme traumatic mind harm in youngsters (Cool Children): a section 3, randomised managed trial. Lancet Neurol. 2013;12:546–53.
Beca J, McSharry B, Erickson S, Yung M, Schibler A, Slater A, et al. Hypothermia for traumatic mind harm in youngsters—a section II randomized managed trial. Crit Care Med. 2015;43:1458–66.
Collaborators CT. Impact of intravenous corticosteroids on dying inside 14 days in 10 008 adults with clinically vital head harm (MRC crash trial): randomised placebo-controlled trial. Lancet. 2004;364:1321–8.
Robertson CS, McCarthy JJ, Miller ER, Levin H, McCauley SR, Swank PR. Part II medical trial of atorvastatin in gentle traumatic mind harm. J Neurotrauma. 2017;34:1394–401.
Skolnick BE, Maas AI, Narayan RK, Van Der Hoop RG, MacAllister T, Ward JD, et al. A medical trial of progesterone for extreme traumatic mind harm. N Engl J Med. 2014;371:2467–76.
Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA. Ander DS: defend: a randomized medical trial of progesterone for acute traumatic mind harm. Ann Emerg Med. 2007;49:391–402. e392.
Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM. Very early administration of progesterone for acute traumatic mind harm. N Engl J Med. 2014;371:2457–66.
Bramlett HM, Dietrich WD. Lengthy-term penalties of traumatic mind harm: present standing of potential mechanisms of harm and neurological outcomes. J Neurotrauma. 2015;32:1834–48.
Maas AI, Stocchetti N, Bullock R. Average and extreme traumatic mind harm in adults. Lancet Neurol. 2008;7(8):728–41.
Nowak M, Helgeson ME, Mitragotri S. Supply of nanoparticles and macromolecules throughout the blood–mind barrier. Adv Ther. 2020;3:1900073.
Diaz MD, Kandell RM, Wu JR, Chen A, Christman KL, Kwon EJ. Infusible extracellular matrix biomaterial promotes vascular integrity and modulates the inflammatory response in acute traumatic mind harm. Adv Healthc Mater. 2023;12:2300782.
Kudryashev JA, Madias MI, Kandell RM, Lin QX, Kwon EJ. An activity-Based mostly nanosensor for Minimally‐Invasive measurement of protease exercise in traumatic mind harm. Adv Funct Mater. 2023;33:2300218.
Lagraoui M, Sukumar G, Latoche JR, Maynard SK, Dalgard CL, Schaefer BC. Salsalate remedy following traumatic mind harm reduces irritation and promotes a neuroprotective and neurogenic transcriptional response with concomitant practical restoration. Mind Behav Immun. 2017;61:96–109.
Roth TL, Nayak D, Atanasijevic T, Koretsky AP, Latour LL, McGavern DB. Transcranial amelioration of irritation and cell dying after mind harm. Nature. 2014;505:223–8.
Sharma R, Kambhampati SP, Zhang Z, Sharma A, Chen S, Duh EI, et al. Dendrimer mediated focused supply of sinomenine for the remedy of acute neuroinflammation in traumatic mind harm. J Managed Launch. 2020;323:361–75.
Zhu Y, Wang H, Fang J, Dai W, Zhou J, Wang X, Zhou M. SS-31 offers neuroprotection by reversing mitochondrial dysfunction after traumatic mind harm. Oxidative Drugs and Mobile Longevity 2018, 2018:4783602.
Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She Z-G, Kotamraju VR, Ranscht B. A peptide for focused, systemic supply of imaging and therapeutic compounds into acute mind accidents. Nat Commun. 2016;7:11980.
Ruoslahti E. Molecular ZIP codes in focused drug supply. Proc Natl Acad Sci U S A. 2022;119:e2200183119.
Mu X, He H, Wang J, Lengthy W, Li Q, Liu H, Gao Y, Ouyang L, Ren Q, Solar S, et al. Carbogenic nanozyme with ultrahigh reactive nitrogen species selectivity for traumatic mind harm. Nano Lett. 2019;19:4527–34.
Waggoner LE, Miyasaki KF, Kwon EJ. Evaluation of PEG-lipid anchor size on lipid nanoparticle pharmacokinetics and exercise in a mouse mannequin of traumatic mind harm. Biomater Sci. 2023;11:4238–53.
Han S, Yoo W, Carton O, Joo J, Kwon EJ. Pegylated multimeric RNA nanoparticles for siRNA supply in traumatic mind harm. Small. 2025;21:2405806.
Kandell RM, Wu JR, Kwon EJ. Reprograming clots for in vivo chemical concentrating on in traumatic mind harm. Adv Mater. 2024;36:2301738.
